Johnson & Johnson, (JNJB34) Fair Value & Analysis
Healthcare · BR · Market cap R$2.8T
Fair value as of: Jun 24, 2026
From 25 valuation models · updated 7 days ago
Share price +17.0% over the past month.
Price vs Fair Value (12 months)
12‑month range R$50.77 – R$83.32 · fair‑value band R$7.64 – R$17.69 · the R$82.49 price screens above the R$12.18 fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Johnson & Johnson, (JNJB34) currently trades at R$82.49, while our model-based Fair Value estimate is R$12.18 — implying the stock looks roughly 85.2% overvalued today. We read business quality at 84/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Johnson & Johnson, generated revenue of R$96.4B at a net margin of 21.8%. Revenue grew 9.9% year over year. It earns a return on equity of 26.4%. Net debt stands at R$28.2B. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Johnson & Johnson, reported revenue of R$94.2B in FY2025 versus R$93.8B in FY2021, a compound +0.1%/yr. Reported net income was R$26.8B in FY2025, compounding +6.4%/yr from FY2021.
Is JNJB34 fairly valued? → Check now
Recent news
- J&J Wins CHMP Nod for Expanded Use of Multiple Myeloma Drug Tecvayli
- Is SYRE Stock a Buy Now or a Wait-and-See Biotech Story Today
- SYRE and Spyre Ride New IBD Trends in Biotech Drug Design
- Spyre Therapeutics Stock Outlook Hinges on 2026 Study Catalysts
External third-party headlines (Yahoo Finance, Reuters and others) — not an editorial selection, not financial advice.
Similar stocks
6 more Drug Manufacturers - General stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Eli Lilly and Company LLY | $1,102 | $395.92 | -64% |
| JNJ JNJ | 4,128 MXN | 159.68 MXN | -96% |
| AbbVie Inc ABBV | $224.94 | $109.04 | -52% |
| Roche Holding ROGN | 7,050 MXN | 6,743 MXN | -4% |
| Merck & Co MRK | $119.09 | $77.57 | -35% |
| AstraZeneca PLC A1ZN34 | R$157.11 | R$108.37 | -31% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Johnson & Johnson, (JNJB34) undervalued?
What is the fair value of JNJB34?
What is the quality score of JNJB34?
What is the revenue of Johnson & Johnson, (JNJB34)?
What is the net profit margin of JNJB34?
Does Johnson & Johnson, pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.